BioHybrid Solutions (BHS) develops next-generation biopolymer hybrids, tailoring the activity and stability of proteins and enzymes for a wide range of applications including therapeutics, bioenergy, industrial catalysis, biosensors, and medical devices.
BHS is focused on opportunities in therapeutics, biocatalysis, diagnostics, and devices. Polymer-modified enzymes dramatically improve biocatalytic processes, resulting in higher throughput, less waste, and lower costs. In therapeutics, polymer-modified proteins can open new routes of administration (e.g. injectable to oral), improve pharmacokinetics, and reduce immunogenicity. Novel biosensors, diagnostics, and devices are made possible through advanced protein stabilization and functionalization.
BioHybrid Solutions is leveraging 10+ years and millions of dollars of academic development to begin addressing real world problems.
Developed at Carnegie Mellon University
BHS was founded by Drs. Alan Russell and Krzysztof Matyjaszewski of Carnegie Mellon University to commercialize their “grown-from” approach to constructing protein-polymer conjugates using atom transfer radical polymerization (ATRP) chemistry.